Abstract
1242P - Clinical utility of precision immunoprofiling and monitoring of the tumour microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: Results from a phase II study for biomarker analysis (EPOC1702)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have